Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Acquires 5,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, July 10th. The stock was bought at an average cost of $3.04 per share, for a total transaction of $15,200.00. Following the purchase, the chief executive officer owned 635,812 shares in the company, valued at $1,932,868.48. This represents a 0.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Stock Performance

Anixa Biosciences stock opened at $3.06 on Tuesday. The stock has a fifty day moving average of $2.80 and a two-hundred day moving average of $2.90. The company has a market capitalization of $104.10 million, a price-to-earnings ratio of -9.87 and a beta of 0.59. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Analyst Ratings Changes

ANIX has been the topic of a number of recent research reports. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Finally, Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.50.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ANIX. Segall Bryant & Hamill LLC acquired a new position in Anixa Biosciences during the first quarter valued at approximately $45,000. Renaissance Technologies LLC increased its position in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after acquiring an additional 7,300 shares in the last quarter. Kestra Advisory Services LLC raised its stake in shares of Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after acquiring an additional 25,000 shares during the period. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter valued at $161,000. Finally, Millennium Management LLC acquired a new position in shares of Anixa Biosciences during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.